Urology Doctors in Fayetteville, NC Accepting Medicare

6 Urology doctors found. Showing 1 - 6

Dr. Henry Edward Parfitt Jr., M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1786 Metromedical Dr, Fayetteville, NC 28304 Phone: 910-485-8151    Fax: 910-485-2963

Hernando Salcedo, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 2301 Robeson St, Suite 203, Fayetteville, NC 28305 Phone: 910-615-3220    Fax: 910-486-2170

Dr. Robert A Appel, M.D. Urology Medicare: Medicare Enrolled Practice Location: 1786 Metromedical Dr, Fayetteville, NC 28304 Phone: 910-485-8151    Fax: 910-485-2963

Dr. Jeffrey S Jones, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 2300 Ramsey St, Fayetteville, NC 28301 Phone: 800-771-6106    Fax: 910-822-7970

Dr. James Francis Nolan, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1786 Metromedical Dr, Fayetteville, NC 28304 Phone: 910-485-8151    Fax: 910-485-2963

Gary A Haney, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2300 Ramsey St, Fayetteville, NC 28301 Phone: 800-771-6106    Fax: 910-822-7970

News Archive

HemoSep device significantly reduces need for blood transfusions during major surgeries

A pioneering surgical blood salvage technology developed at the University of Strathclyde, Glasgow, is set to transform the way major surgery is carried out by reducing blood loss in patients.

Obama's debt commission to consider Medicare cuts, new health care law

President Obama's bipartisan debt commission met Tuesday to discuss ways to reduce the federal deficit. The President said that everything was up for discussion, including provisions of the federal health care law, and entitlement programs like Medicare and Social Security.

Blues insurers win antitrust case in Mich., see profits increase 20% in Minn.; HMO profit caps mean Minn. will get $8M back from another insurer

Blue Cross and Blue Shield in Michigan won a hospital pricing antitrust case. In Minnesota, nonprofit insurer UCare prepares to return $8 million to the state while Blue Cross and Blue Shield of Minnesota's profit rose 20 percent in 2011.

Octreotide inhibits HepG2 proliferation, study confirms

Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and is estimated to cause approximately half a million deaths annually. Undoubtedly, the best available treatment for all liver tumors is complete surgical resection. However, the synthetic somatostatin analogue octreotide has been found effective in inhibiting tumor growth in a variety of experimental models. It has been reported that octreotide inhibits the proliferation and induces apoptosis of different HCC cell lines in vitro.

Read more Medical News

› Verified 1 days ago